An activist’s guide to rifapentine-based TB prevention (2024)
4 June 2024. Related: TB coinfection, Other news, On the web.
TB coinfection
No increase in adverse birth outcomes with IPT-exposure in pregnancy in two African cohorts
11 November 2020. Related: Conference reports, Pregnancy, TB coinfection.
DR-TB drugs under the microscope: five urgent actions to improve DR-TB treatment (6th edition)
15 November 2019. Related: TB coinfection.
Efavirenz 600 mg exposure appears sufficient with high-dose daily rifapentine
19 June 2019. Related: Conference reports, PK and drug interactions, TB coinfection.
Antiretroviral pharmacokinetics in pregnancy: update from IMPAACT P1026s
19 June 2019. Related: Conference reports, Women's health, Pregnancy, TB coinfection.
FDA advisory committee votes favorably on use of pretomanid with bedaquiline and linezolid for drug-resistant TB
19 June 2019. Related: TB coinfection.
Bedaquiline and delamanid safe when given together to treat drug resistant TB
28 March 2019. Related: Conference reports, TB coinfection.
Isoniazid preventative therapy in HIV positive pregnant women not linked to poor outcomes
28 March 2019. Related: Conference reports, TB coinfection.
Dolutegravir can be given with 3HP to prevent TB without dose adjustment
12 March 2019. Related: Conference reports, PK and drug interactions, TB coinfection.
Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity
12 March 2019. Related: Conference reports, PK and drug interactions, TB coinfection.
BHIVA guidelines for adult TB/HIV coinfection (2018)
20 February 2019. Related: Guidelines, TB coinfection.
Activists demand $1 a day access to bedaquiline for MDR TB
13 November 2018. Related: Treatment access, TB coinfection.
Dolutegravir twice daily is effective and tolerable with rifampicin: 48 week results from the INSPIRING study
19 September 2018. Related: Conference reports, TB coinfection.
Rifabutin dosed 2.5 mg/kg daily with lopinavir/r in children achieves comparable exposure to adults
29 June 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Boosted darunavir 800/100 mg twice daily might overcome interaction with rifampicin
29 June 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Dolutegravir 50 mg twice daily sufficient with rifampicin but levels reduced significantly with 100 mg once daily
8 June 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Isoniazid preventive TB therapy in pregnancy and postpartum: recommendations now need to be re-evaluated
16 April 2018. Related: Conference reports, Women's health, Pregnancy, TB coinfection.
Doubling raltegravir dose could overcome interaction with rifampicin in children aged 2 to 6
16 April 2018. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
Twice-daily bictegravir does not overcome drug interaction with rifampicin
16 April 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Dual therapy can reduce TB prophylaxis from nine months to one: fewer side effects and more people complete treatment
14 March 2018. Related: Conference reports, TB coinfection.
Twice-daily dolutegravir is effective and tolerable with rifampicin
14 March 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Once-daily tenofovir alafenamide appears sufficient when dosed with rifampicin
14 March 2018. Related: Conference reports, TB coinfection.
Efavirenz 400 mg can be given with anti-tuberculosis treatment
14 March 2018. Related: Conference reports, TB coinfection.
Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin
28 November 2017. Related: Conference reports, PK and drug interactions, TB coinfection.
Breakthrough for treating XDR-TB and ameliorating TB-IRIS
24 April 2017. Related: Conference reports, Coinfections and complications, TB coinfection.
Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients
29 November 2016. Related: Conference reports, PK and drug interactions, TB coinfection.
Universal treatment of multi-drug resistant TB is possible within current budgets with generic production
1 August 2016. Related: Conference reports, TB coinfection.
Shortened nine-month MDR-TB treatment works well in children and adolescents
1 August 2016. Related: Conference reports, Paediatric care, TB coinfection.
Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB
1 August 2016. Related: Conference reports, Paediatric care, TB coinfection.
Executive summary – tuberculosis
14 July 2016. Related: Pipeline report, TB coinfection.
The tuberculosis diagnostics pipeline
14 July 2016. Related: Pipeline report, TB coinfection.
The tuberculosis prevention pipeline
14 July 2016. Related: Pipeline report, TB coinfection.
The tuberculosis treatment pipeline: activity, but no answers
14 July 2016. Related: Pipeline report, TB coinfection.
The paediatric tuberculosis treatment pipeline: beyond pharmacokinetics and safety data
14 July 2016. Related: Pipeline report, Paediatric care, TB coinfection.
Promising first results with a 9-month regimen for multidrug resistant tuberculosis in French-speaking African countries
1 February 2016. Related: Conference reports, TB coinfection.
Pharmacokinetics of old and new TB drugs for children
1 February 2016. Related: Conference reports, PK and drug interactions, TB coinfection.
The REALITY trial: cotrimoxazole/isoniazid/pyridoxine tablets are bioequivalent to individual products and are acceptable to participants
1 February 2016. Related: Conference reports, TB coinfection.
Price of MDR TB drugs could be greatly reduced with competitive generic manufacture
1 December 2015. Related: Conference reports, Treatment access, TB coinfection.
Pharmacokinetics of lopinavir/ritonavir super-boosting in infants and young children co-infected with HIV and TB
1 December 2015. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
The Tuberculosis Treatment Pipeline: Moving Beyond “Making the Most of What We’ve Got”
17 July 2015. Related: Pipeline report, TB coinfection.
Momentum in the Pediatric Tuberculosis Treatment Pipeline
17 July 2015. Related: Pipeline report, Paediatric care, TB coinfection.
The Tuberculosis Diagnostics Pipeline
17 July 2015. Related: Pipeline report, Diagnostics, TB coinfection.
The Tuberculosis Vaccines Pipeline: A New Path to the Same Destination?
17 July 2015. Related: Pipeline report, TB coinfection, Vaccines and microbicides.
New clinical trial for extensively drug resistant TB (XDR-TB)
1 June 2015. Related: TB coinfection.
MSF report and call to action: Promising new TB drugs are not reaching patients
1 June 2015. Related: TB coinfection.
Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 counts >500
24 March 2015. Related: Conference reports, Treatment strategies, TB coinfection.
Good outcomes within the National Bedaquiline Clinical Access programme in South Africa
29 January 2015. Related: Conference reports, TB coinfection.
TB in the ARROW trial of children on ART
29 January 2015. Related: Conference reports, Paediatric care, TB coinfection.
Problems giving current second line TB drugs to children
29 January 2015. Related: Conference reports, Paediatric care, TB coinfection.
Treatment outcomes in HIV positive and negative people with drug resistant TB in Khayelitsha, Cape Town
1 December 2014. Related: Conference reports, TB coinfection.
Efavirenz pharmacokinetics among pregnant women with and without tuberculosis coinfection
1 October 2014. Related: Pregnancy, TB coinfection.
The tuberculosis diagnostics pipeline
19 July 2014. Related: Pipeline report, TB coinfection.
Tuberculosis drug development hobbles forward
19 July 2014. Related: Pipeline report, TB coinfection.
Playing catch-up: paediatric tuberculosis treatment pipeline
19 July 2014. Related: Pipeline report, Paediatric care, TB coinfection.
The tuberculosis vaccines pipeline
19 July 2014. Related: Pipeline report, TB coinfection.
Xpert TB test has important advantages but does not reduce morbidity
24 March 2014. Related: Conference reports, TB coinfection.
EMA recommends conditional approval of bedaquiline for drug resistant TB with orphan drug status
1 February 2014. Related: TB coinfection.
Preventing and treating TB in children – more baby steps
1 December 2013. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
Activists call EU failure to approve delaminid for MDR tuberculosis due to limited data both “myopic and disappointing”
1 October 2013. Related: TB coinfection.
Executive summary and research policy recommendations
30 June 2013. Related: Pipeline report, Antiretrovirals, Treatment strategies, Diagnostics, Hepatitis coinfection, TB coinfection.
The tuberculosis diagnostics pipeline
30 June 2013. Related: Pipeline report, Diagnostics, TB coinfection.
The tuberculosis treatment pipeline
30 June 2013. Related: Pipeline report, Treatment strategies, TB coinfection.
The tuberculosis vaccine pipeline
30 June 2013. Related: Pipeline report, TB coinfection, Vaccines and microbicides.
RIFAQUIN study demonstrates once-weekly dosing during follow-up phase of TB treatment
1 April 2013. Related: Conference reports, Coinfections and complications, TB coinfection.
Combining Xpert and LAM urine testing improves TB diagnostic sensitivity
1 April 2013. Related: Conference reports, Diagnostics, Coinfections and complications, TB coinfection.